• GPI Home
  • Solutions
    • GPI pulse™
    • GPI Consulting
    • GPI Horizon Methodology
    • Case Studies
  • About Us
    • Our Team
    • Careers
  • Contact Us
  • Discover
    • Blog
    • Events
    • Resources
  • GPI Direct
market access
October 2, 2020 by Global Pricing Innovations (GPI)
Medicine Manufacturers Hit Hard by Latest French Healthcare Finance Reforms

Spending Changes Recently the French government has published its Social Security Finance Bill 2021 (PLFSS 2021), which covers the annual review of their health and social security expenditure. With the impact of COVID-19 increasing there seems to be an ever-increasing cost cutting exercise…

August 7, 2020 by Global Pricing Innovations (GPI)
Whitepaper: Indication based pricing – Widely advocated but not yet feasible

Find out how the notion of value based pricing methodologies are becoming more common place in pharmaceutical medicines pricing and how Indication-based pricing (IBP) has been proposed as a potential solution for any medicine that offers benefits across many different indications. In this…

June 25, 2020 by Global Pricing Innovations (GPI)
GPI WEBINAR: Orphan price and access forecasting – a Must for return on investment in changing times

Click HERE to Register At GPI, working daily with price and reimbursement data, we have seen a range of PMA trends across high unmet need areas such as orphan/rare diseases. Increasing pharma focus on rare diseases resulted in payers having to adapt their…

April 16, 2020 by Global Pricing Innovations (GPI)
A Change in Priorities – How COVID-19 Has Changed the Public and Private Sector

By Ines Dieringer, Associate Consultant  The COVID-19 crisis has altered the way in which vaccines and drugs are developed and approved. In the private sector, we see unprecedented partnerships arise, while the public sector has experienced a policy shift towards a system of…

March 20, 2020 by Global Pricing Innovations (GPI)
UPDATED – Webinar: Early Price and Access Forecasting (WFH Edition)

We hope you are all safe and in good health. At GPI, we are extremely proud to present our new offering, GPI HORIZON, an innovative methodology supporting early price and access forecasting. Despite the uncertainty and change brought by COVID-19 outbreak, GPI have…

March 17, 2020 by Global Pricing Innovations (GPI)
GPI makes market access more efficient with pioneering partnership with Sisense-enabled analytics platform

Pricing & Market Access leader enhances pricing database with world’s leading analytics platform for technology developers  London, UK, March 17, 2020 – Global Pricing Innovations (GPI), a leader in analytical market access solutions for biopharma, has announced the Spring 2020 release of new features…

SiSense Logo
GPI Pulse used in Spain
March 10, 2020 by Global Pricing Innovations (GPI)
Spain introduces exclusive pricing scheme for new orphan drugs. How will this affect International Reference Pricing?

Author – Nairuti Patel (Associate Consultant, GPI) On 3rd March 2020, the Spanish Council of Ministers announced a ‘specific pricing system’ for orphan medicinal product that will be separate from the reference pricing system. The reference pricing system applies to all other products reimbursed by the Spanish National Health System (SNS) when their patent has expired. The only instance when orphan drugs will be included in this new…

February 25, 2020 by Global Pricing Innovations (GPI)
GPI will be sponsoring the drinks reception at World Pharma Pricing Market Access & Evidence Congress 2020

Global Pricing Innovations will be sponsoring the drinks reception at World Pharma Pricing Market Access and Evidence Congress 2020 on the 18th March 2020 at Amsterdam’s Beurs van Berlage venue. GPI will be officially launching and providing an exclusive sneak peak at our…

GPI is the sponsor of the drinks reception at PPMA 2020. Join us on the 18th of march!
Novartis Building
February 20, 2020 by Global Pricing Innovations (GPI)
Capmatinib: The Race to Approval and Optimal Pricing

By Ines Dieringer – Associate Consultant With new mutations which are driving oncogenesis in life-threatening cancers being discovered everyday, the industry looks be keeping pace with targeted therapies for these mutagenic targets. One such example is Novartis’ investigational therapy Capmatinib. This investigational therapy…

February 18, 2020 by Global Pricing Innovations (GPI)
GPI attending World Pharma Pricing, Market Access and Evidence Congress

Global Pricing Innovations will be attending the World Pharma Pricing, Market Access & Evidence Congress in Amsterdam on the 18th and 19th March 2020. Please reach out to our Business Development Manager to arrange a meeting at the event. Musa Kureshy – Business…

GPI will be attending PPMA 2020. See you there!
GPI forecasts price potential by correlating pricing and access data with real-world payer behavior
October 22, 2019 by Global Pricing Innovations (GPI)
Global Pricing Innovations (GPI) forecasts drug price potential using advanced analytics

  Today Global Pricing Innovations (GPI) reports that it has validated an analytical method for forecasting new drug price potential during early stage development, opening a pathway to digital transformation for teams engaged in pricing and market access. GPI has successfully forecasted prices…

October 18, 2019 by Global Pricing Innovations (GPI)
Novartis’s gene therapy Luxturna receives ‘considerable added benefit’ in Germany

  Luxturna (voretigen neparvovec), a gene therapy developed by Novartis, received ‘considerable added benefit’ from G-BA, the German health technology assessment. Luxturna is a one-off treatment for vision loss in adults and children, caused by retinal dystrophy from mutations in both copies of…

Novartis building
October 1, 2019 by Global Pricing Innovations (GPI)
Pharma price and access pioneers, Global Pricing Innovations (GPI), continue growth with the strategic expansion to Cambridge, UK.

New office expansion enables GPI to accelerate growth in software engineering, professional services and customer support.   London, October 1st, 2019 Global Pricing Innovations (GPI), today announced the opening of its second UK office in Cambridge, UK which will help to strengthen the…

September 25, 2019 by Global Pricing Innovations (GPI)
What the Beneluxa Group is aiming for next

BeNeLuxA collaboration is a joint initiative on drug pricing and reimbursement between the governments of Belgium, The Netherlands, Luxembourg, Austria and Ireland, with the aim of giving smaller countries greater negotiating power in discussing drug pricing with international drug firms. The group was…

What the Beneluxa Group is aiming for next
September 23, 2019 by Global Pricing Innovations (GPI)
With the Updated Stability Programme 2019-2022, Spanish government reinforces healthcare budget control measures

In April 2019, the Spanish government submitted its ‘Updated Stability Program for 2019-2022’ to the European Union, reiterating the commitment to keep the national healthcare expenditure to 6% of the GDP. New and continuing budget control measures targeting the pharmaceutical expense, which comprise 19%…

August 30, 2019 by Global Pricing Innovations (GPI)
Roche’s Tecentriq in combination with Abraxane approved for metastatic triple-negative breast cancer in Europe.

  Roche announced on Thursday, August 29, that Tecentriq (atezolizumab) in combination with Abraxane (protein-bound paclitaxel) had been approved in Europe for patients with PD-L1-positive, metastatic triple-negative breast cancer (TNBC). The Tecentriq combination marks the first cancer immunotherapy regimen to be available in…

August 23, 2019 by Global Pricing Innovations (GPI)
US Government is considering introduction of International Reference Pricing

President Trump’s administration has proposed to create an International Pricing Index (IPI) model for Medicare Plan B, which could bring international reference pricing (IRP) to the United States. The proposed change would apply to physician-administered therapies (covered by Medicare Part B) but not…

August 19, 2019 by Global Pricing Innovations (GPI)
Canada finalises new regulations to tackle high drug prices

  Earlier this month, the Government of Canada announced the final amendments to the Patented Medicines Regulations which estimates to save Canadians around $13 billion in the next decade and lay the foundation for National Pharmacare. The most significant reform to the regulations since…

June 19, 2019 by Global Pricing Innovations (GPI)
The new Pricing System in Russia will lead to price decreases for many medicines

  Amendments to the Pharmaceutical Law in Russia will take effect from June 2019 and will be completed by 1st January 2021. Medicines which are reimbursed in Russia are listed on the Essential Drugs List (EDL), in which there are currently 735 products,…

June 4, 2019 by Global Pricing Innovations (GPI)
Analytics and Forecasting for efficient business development, early pricing and target product profile optimisation.

Learn how GPI’s ground-breaking new approach to early price setting and TPP optimisation can quantify the value of your product, predict payer response and forecast price potential. Obtain unbiased, rapid insights in days, not months, saving you time and resources.

June 3, 2019 by Global Pricing Innovations (GPI)
Prices of Pfizer’s leukaemia drug Bosulif cut by 13% in Germany after HTA

  The retail prices of Pfizer’s leukaemia drug Bosulif (bosutinib) were cut by 13% in Germany on 1 June. This is likely a result of recent price negotiations with GKV-Spitzenverband payer group. Per AMNOG procedure, the negotiations were triggered by Bosulif losing its…

May 15, 2019 by Global Pricing Innovations (GPI)
New set of rules regulating medicine prices in Kazakhstan

  New pharmaceutical pricing rules were approved this past April in Kazakhstan. The new price control measures extended their scope from medicines within the state procurement system to pharmaceutical products sold in private marketing channels, such as in wholesale and pharmacies. In addition,…

May 7, 2019 by Global Pricing Innovations (GPI)
Malaysian authorities approve the introduction of IRP

  Earlier this month, the Malaysian Ministry of Health has approved the introduction of international reference pricing (IRP) to benchmark medicines prices and ‘expand access to expensive new medicines’. A ceiling price will be derived from the average of the three lowest prices…

March 18, 2019 by Global Pricing Innovations (GPI)
Employee Spotlight – Madhuri Chhatbar

  Madhuri Chhatbar HR Manager Joined GPI in September 2018 Kicking off our Tuesday with our next employee spotlight – Madhuri Chhatbar. Madhuri is our HR manager out in our Mumbai office and plays a crucial part not only with our employees but…

September 21, 2018 by Global Pricing Innovations (GPI)
Taking stock:  European cross-border cooperation on medicines’ value-assessment, and Pricing & Reimbursement negotiations  

Fertile ground for cross-border cooperation Even with pan-European EMA approval, pricing is still a country-level issue, with national governments, regional or local stakeholders and pharmaceutical companies being responsible for engaging in price formalities such as negotiations on a bilateral basis. But the landscape…

January 23, 2018 by Global Pricing Innovations (GPI)
What will shape the global pharmaceutical pricing environment in 2018?

One of the advantages of working in a global consultancy and technology solutions firm such as Global Pricing Innovations (GPI), which specializes in pharmaceutical pricing, is the wide exposure one receives to the many different challenges across disease areas, companies, and geographies. This…

December 22, 2017 by Global Pricing Innovations (GPI)
Season's Greetings from GPI
Our partners
  • Privacy Policy
  • Terms of Use

| © Copyright 2018 Global Pricing Innovations. All Rights Reserved.

VAT registration: GB225169121